Powering Precision Medicine - Trends Shaping the CGT Market

The global Cell and Gene Therapy (CGT) market is entering a high-growth phase, set to reach USD 53.7 billion by 2026 on the back of rising adoption, regulatory support, and strong deal momentum. With over 3,900 candidates in development—most targeting oncology—and major players like AstraZeneca, Roche, and Novartis making billion-dollar acquisitions, CGT is emerging as a cornerstone of precision medicine. Innovations in non-viral delivery, AI-enabled manufacturing, and engineered cell therapies are driving scalability, safety, and access across therapeutic areas.